Photodynamic Therapy for Chronic Rhinosinusitis

The patent converts the harmful presence of pathogens into a beneficial treatment outcome by using photodynamic therapy. The photosensitizing agent specifically targets and eliminates infectious microorganisms (including resistant strains like MRSA and Pseudomonas) through light activation, transforming the pathological state into a therapeutic opportunity that prevents recurrence and resistance development.

The patent replaces the mechanical surgical intervention (functional endoscopic sinus surgery) with a non-mechanical photodynamic therapy approach. Instead of physically removing tissue through surgery, the treatment uses photosensitizing agents activated by light energy to selectively destroy pathogens, avoiding the harmful effects of surgical trauma and pathogen emergence while maintaining therapeutic effectiveness.

The patent converts the problem of bacterial resistance into a solution by using photodynamic therapy that operates through a non-specific cytotoxic mechanism. The photosensitizing agent generates reactive oxygen species that damage microbial cells through oxidative stress, a mechanism that does not rely on traditional antibiotic targets, thereby preventing the development of resistance while effectively controlling infectious microorganisms.

The patent changes the fundamental parameter of treatment mechanism from chemical inhibition (antibiotics) to photochemical destruction (photodynamic therapy). By using light activation of photosensitizing agents, the treatment achieves microorganism control through a different physical-chemical pathway that does not select for resistant strains, effectively addressing the resistance problem while maintaining therapeutic reliability.

The patent applies local quality by using a photosensitizing agent that selectively accumulates at the treatment site where pathogens are present. The agent is activated by light energy only in the localized area of infection, creating a highly concentrated therapeutic effect precisely where needed while leaving surrounding healthy tissues unaffected, thus achieving effective pathogen elimination without causing unnecessary tissue damage or pain.

The patent introduces a photosensitizing agent as an intermediary substance that mediates between the light energy source and the target pathogens. This intermediary selectively localizes at the infection site and converts light energy into cytotoxic effects only where required, acting as a targeted delivery mechanism that protects surrounding healthy tissues from direct light exposure and its potential harmful effects.